Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - Taylor & Francis
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
[HTML][HTML] Remicade®(infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets & …, 2019 - ncbi.nlm.nih.gov
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
[HTML][HTML] Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - dovepress.com
On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF) inhibitor,
received its initial marketing approval from the US Food and Drug Administration for the …
received its initial marketing approval from the US Food and Drug Administration for the …
Remicade®(infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof… - Biologics: targets & …, 2019 - pubmed.ncbi.nlm.nih.gov
On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF) inhibitor,
received its initial marketing approval from the US Food and Drug Administration for the …
received its initial marketing approval from the US Food and Drug Administration for the …
Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza, T Schaible - Biologics, 2019 - search.proquest.com
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
Remicade [R](infliximab): 20 years of contributions to science and medicine.
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - go.gale.com
Prompted by the recent twentieth anniversary of the first approval of Remicade [R](infliximab;
Janssen Biotech, Inc., Horsham, PA, USA), a first-in-class monoclonal antibody tumor …
Janssen Biotech, Inc., Horsham, PA, USA), a first-in-class monoclonal antibody tumor …
[PDF][PDF] Remicade®(infliximab): 20 years of contributions to science and medicine
R Melsheimer - Biologics: Targets and Therapy, 2019 - pdfs.semanticscholar.org
On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF) inhibitor,
received its initial marketing approval from the US Food and Drug Administration for the …
received its initial marketing approval from the US Food and Drug Administration for the …
Remicade® (infliximab): 20 years of contributions to science and medicine.
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets & …, 2019 - europepmc.org
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - dovepress.com
On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF) inhibitor,
received its initial marketing approval from the US Food and Drug Administration for the …
received its initial marketing approval from the US Food and Drug Administration for the …